ALDH2 Mediates 5-Nitrofuran Activity in Multiple Species

Linna Zhou(University of St Andrews), Hironori Ishizaki(Edinburgh Cancer Research), Michaela Spitzer(Wellcome Centre for Cell Biology), Kerrie L. Taylor(Institute of Genetics and Cancer), Nicholas D. Temperley(Edinburgh Cancer Research), Stephen L. Johnson(Washington University in St. Louis), P. Brear(Edinburgh Cancer Research), Philippe Gautier(Institute of Genetics and Cancer), Zhiqiang Zeng(Institute of Genetics and Cancer), Amy Mitchell(Edinburgh Cancer Research), Vikram Narayan(Edinburgh Cancer Research), Ewan M. McNeil(Edinburgh Cancer Research), David W. Melton(Edinburgh Cancer Research), Terry Smith(University of St Andrews), Mike Tyers(Wellcome Centre for Cell Biology), Nicholas J. Westwood(University of St Andrews), E. Elizabeth Patton(Edinburgh Cancer Research)
Chemistry & Biology
July 1, 2012
Cited by 53Open Access
Full Text

Abstract

Understanding how drugs work in vivo is critical for drug design and for maximizing the potential of currently available drugs. 5-nitrofurans are a class of prodrugs widely used to treat bacterial and trypanosome infections, but despite relative specificity, 5-nitrofurans often cause serious toxic side effects in people. Here, we use yeast and zebrafish, as well as human in vitro systems, to assess the biological activity of 5-nitrofurans, and we identify a conserved interaction between aldehyde dehydrogenase (ALDH) 2 and 5-nitrofurans across these species. In addition, we show that the activity of nifurtimox, a 5-nitrofuran anti-trypanosome prodrug, is dependent on zebrafish Aldh2 and is a substrate for human ALDH2. This study reveals a conserved and biologically relevant ALDH2-5-nitrofuran interaction that may have important implications for managing the toxicity of 5-nitrofuran treatment.


Related Papers